Evidence map›Paper›PMID 34262257›Full record

ArticleDrug design, development and therapy2021

Evaluation of Ceftazidime/Avibactam Administration in

Yuanyuan Dai, Wenjiao Chang, Xin Zhou, Wei Yu, Chen Huang, Yunbo Chen, Xiaoling Ma, Huaiwei Lu, Rujin Ji, Chaoqun Ying and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Yuanyuan DaiDepartment of Laboratory, First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
Wenjiao ChangDepartment of Laboratory, First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
Xin ZhouDepartment of Laboratory, First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
Wei YuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.
Chen HuangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.
Yunbo ChenState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.ORCID 0000-0002-5843-1386
Xiaoling MaDepartment of Laboratory, First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
Huaiwei LuDepartment of Laboratory, First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
Rujin JiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.ORCID 0000-0003-1579-2250
Chaoqun YingState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.ORCID 0000-0001-8599-3838
Peipei WangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.ORCID 0000-0002-5873-8732
Zhiying LiuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.ORCID 0000-0002-2060-1597
Qingfeng YuanDepartment of Laboratory, First Affiliated Hospital of University of Science and Technology of China, Hefei, People's Republic of China.
Yonghong XiaoState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.
National Clinical Research · USUniversity of Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the administration regimen of ceftazidime/avibactam (CZA) for bloodstream infections caused by

methodsThe minimal inhibitory concentrations (MICs) of CZA against

resultsAltogether, 6487

conclusionCZA has good antibacterial activity against

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsBacteremiaCeftazidimeComputer SimulationDose-Response Relationship, DrugDrug CombinationsDrug Resistance, BacterialEnterobacteriaceaeEnterobacteriaceae InfectionsHumansMicrobial Sensitivity TestsMonte Carlo MethodPseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug Combinationsdosage regimensextended-spectrum β-lactamaseGram-negative bacteriaminimum inhibitory concentrationpharmacodynamicspharmacokinetics

Identifiers

PMID34262257
PMCPMC8275101
OpenAlexW3180808600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.